Poseida Therapeutics

Poseida Therapeutics

Poseida Therapeutics is a poseida Therapeutics develops targeted cell therapy.

Poseida Therapeutics is a privately held, biopharmaceutical company based in San Diego California. It leverages proprietary non-viral, gene engineering technologies to create therapeutics for illnesses with high unmet medical needs. The company is developing a wholly-owned pipeline of autologous and allogenic CAR-T product candidates, initially focused on the treatment of hematological malignancies and other solid tumors.

Poseida's leading product candidate is P-BCMA-101, an autologous CAR-T product that targets B cell maturation antigen, or BCMA, which is expressed on multiple myeloma cells. In December 2018, the company announced positive results from its first cohort of ongoing Phase 1 clinical trial. Poseida's second autologous product is P-PSMA-101, targeting cells that express prostate-specific membrane antigen, which is expressed on most prostate cancer cells. The product is being developed to treat patients with castrate-resistance prostate cancer, or CRPC, a solid tumor indication, with Phase 1 clinical trials planned in the second half of 2019.

Under the allogenic category, Poseida has P-BCMA-ALL01 and P-MUC1C-101. Derived from healthy donors, P-BCMA-ALL01 is designed to have the same inherent properties and functions of P-BCMA-101, but with the benefits of scale and administration efficiency that come from an allogenic product. The company plans to file an IND and begin Phase 1 clinical trials by late 2019 or early 2020. As for P-MUC1C-101, the product is in late-stage pre-clinical development for multiple solid tumor indications with plans for Phase 1 clinical trials in 2020.

In January 2019, Poseida Therapeutics filed documents for an IPO of $115 million.


April 2018

Poseida Therapeutics raises a $30,500,000 series B round from Longitude Capital, Tavistock Group, Malin Corporation and Vivo Capital.

Funding rounds

Funding round
Funding type
Funding round amount (USD)
Funding round date
1 Result
Page 1 of 1
Results per page:
Powered by Golden Research Engine



Debra Gessner

VP, Regulatory Affairs

Devon J. Shedlock

VP, Preclinical Development

Eric Ostertag


Glenn Dourado

VP, Business Development

Jeff Knight

VP, Clinical Development Operations and Project Management

Jennifer Collins

VP, Quality Operations

Johanna Mylet

VP, Finance

Marcy Graham

VP, Corporate Affairs

Mark J. Gergen

Chief Business Officer and Chief Financial Officer

Martin Giedlin

VP, Technical Operations

Matthew A. Spear

Chief Medical Officer

Paiman Peter Ghoroghchian

Chief Technical Officer

Further reading


Poseida Therapeutics Provides Update on Phase 1 Study of P-BCMA-101 CAR-T Product Candidate at the 2018 American Society of Hematology Annual Meeting

Poseida Therapeutics, Inc.


Xconomy: Poseida Therapeutics Prepares for IPO to Advance CAR-T Treatments


Documentaries, videos and podcasts





Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.